Ever Supreme Bio Technology Inkomsten in het verleden
We zijn nog bezig met het verwerken van het laatste winstrapport van dit bedrijf
Verleden criteriumcontroles 4/6
Ever Supreme Bio Technology has been growing earnings at an average annual rate of 58.6%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 51.5% per year. Ever Supreme Bio Technology's return on equity is 33.1%, and it has net margins of 62%.
Belangrijke informatie
58.6%
Groei van de winst
58.7%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 12.2% |
| Inkomstengroei | 51.5% |
| Rendement op eigen vermogen | 33.1% |
| Nettomarge | 62.0% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Ever Supreme Bio Technology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 824 | 511 | 49 | 103 |
| 31 Mar 24 | 805 | 446 | 49 | 101 |
| 31 Dec 23 | 758 | 539 | 48 | 99 |
| 30 Sep 23 | 683 | 571 | 45 | 95 |
| 30 Jun 23 | 628 | 335 | 41 | 95 |
| 31 Mar 23 | 621 | 326 | 40 | 90 |
| 31 Dec 22 | 628 | 201 | 40 | 91 |
| 30 Sep 22 | 603 | 153 | 45 | 97 |
| 30 Jun 22 | 575 | 348 | 45 | 85 |
| 31 Mar 22 | 513 | 374 | 43 | 87 |
| 31 Dec 21 | 439 | 370 | 45 | 84 |
| 30 Sep 21 | 310 | 261 | 39 | 79 |
| 30 Jun 21 | 193 | 15 | 36 | 90 |
| 31 Mar 21 | 112 | -94 | 35 | 100 |
| 31 Dec 20 | 71 | -107 | 30 | 109 |
| 30 Sep 20 | 53 | -118 | 42 | 119 |
| 30 Jun 20 | 28 | -124 | 43 | 110 |
| 31 Mar 20 | 19 | -102 | 43 | 100 |
| 31 Dec 19 | 11 | -94 | 43 | 95 |
| 30 Sep 19 | 2 | -80 | 30 | 89 |
| 30 Jun 19 | 0 | -85 | 29 | 92 |
| 31 Mar 19 | 0 | -77 | 25 | 83 |
| 31 Dec 18 | 0 | -69 | 21 | 73 |
| 30 Sep 18 | 0 | -56 | 17 | 60 |
| 30 Jun 18 | 0 | -43 | 13 | 46 |
| 31 Mar 18 | 0 | -37 | 12 | 38 |
| 31 Dec 17 | 0 | -31 | 11 | 29 |
Kwaliteitswinsten: 6712 has a large one-off gain of NT$170.3M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: 6712's current net profit margins (62%) are higher than last year (53.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 6712 has become profitable over the past 5 years, growing earnings by 58.6% per year.
Versnelling van de groei: 6712's earnings growth over the past year (52.5%) is below its 5-year average (58.6% per year).
Winst versus industrie: 6712 earnings growth over the past year (52.5%) exceeded the Biotechs industry 33.2%.
Rendement op eigen vermogen
Hoge ROE: 6712's Return on Equity (33.1%) is considered high.